You are here

Publications

Found 384 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is G  [Clear All Filters]
2026
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Vinette V, Castro A, Kim H, Trujillo C, Xie M, Gengenbacher M, Ioerger TR, Ehrt S.  2026.  Interstitial and recruited macrophages prevent tuberculosis relapse by limiting immune evasion.. EMBO Mol Med.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al..  2026.  A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.
Khonde LPeguy, Peton N, Masike K, Valentine T, Zindo F, Fienberg S, Omollo C, Njoroge M, Vallini F, Tammaro C et al..  2026.  Structure-Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors.. Eur J Med Chem. 312:118841.